Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Fineline Cube May 18, 2026
Company Drug

Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy

Fineline Cube May 18, 2026
Company

Boehringer Ingelheim Expands Greek Facility to Boost Production of Jardiance and Other Medications

Fineline Cube Jan 12, 2024

Boehringer Ingelheim (BI), headquartered in Germany, has commenced the expansion of its manufacturing facility in...

Company

Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment

Fineline Cube Jan 12, 2024

Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG:...

Company Drug

Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management

Fineline Cube Jan 12, 2024

Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...

Company Drug

AbbVie’s Lutikizumab Advances to Phase III for Hidradenitis Suppurativa After Positive Mid-Stage Results

Fineline Cube Jan 12, 2024

AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following...

Company

Changchun High & New Technology to Transfer 7.42% Stake to Ex-Wife in Divorce Settlement

Fineline Cube Jan 12, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has announced plans to transfer...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Combined Phase Ib/II Study of BAT7104 and BAT4706

Fineline Cube Jan 12, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a Chinese biopharmaceutical company, has announced that it has received...

Company Drug

Eisai’s Lemborexant Sleep Aid Lemborexant Filed for NMPA Approval in China

Fineline Cube Jan 12, 2024

The China Center for Drug Evaluation (CDE) website has indicated that Japan-based Eisai (TYO: 4523)...

Company

Astellas Pharma Appoints Zhao Ping as Chairman of China Operations

Fineline Cube Jan 12, 2024

Effective January 15, 2024, Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has appointed...

Company Deals

Keylights Biotechnology Raises $14 Million in Series B to Expand IVD Instrument Range

Fineline Cube Jan 12, 2024

Keylights Biotechnology Co., Ltd., a leading in vitro diagnostic (IVD) instruments manufacturer headquartered in Shenzhen,...

Company Drug

Joincare Pharmaceutical’s Partner Fermion Gets NMPA Green Light for Pain Drug Clinical Study

Fineline Cube Jan 12, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced that...

Company Deals

Gansu Deshengtang Partners with RELEX Solutions to Enhance Supply Chain Efficiency

Fineline Cube Jan 12, 2024

Gansu Deshengtang Medical Science and Technology Group Co., Ltd, a prominent Chinese healthcare group, has...

Company Drug

GSK Secures Second Indication Approval for Nucala in China for Severe Eosinophilic Asthma

Fineline Cube Jan 11, 2024

GSK plc (NYSE: GSK) has received approval for a second indication in China for its...

Company Deals

China Resources Medical Laboratory Partners with Qlife Lab for Comprehensive Mass Spectrometry Solutions

Fineline Cube Jan 11, 2024

China Resources Medical Holdings Company Limited’s subsidiary, China Resources (Guangdong) Medical Laboratory Co., Ltd, has...

Company Deals

WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal

Fineline Cube Jan 11, 2024

WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...

Company Deals

Junshi Biosciences Regains Global Rights to JS006 as Coherus Terminates Licensing Agreement

Fineline Cube Jan 11, 2024

Junshi Biosciences (HKG: 1877; SHA: 688180), based in Suzhou, has announced the termination of its...

Policy / Regulatory

China’s NHC Unveils Strategy to Enhance Pediatric Healthcare by 2025

Fineline Cube Jan 11, 2024

The National Health Commission (NHC) has issued a set of Opinions aimed at “Promoting the...

Company Deals

Amgen Licenses XeriJect Technology from Xeris Biopharma for Subcutaneous Tepezza Development

Fineline Cube Jan 11, 2024

Amgen (NASDAQ: AMGN) has entered into a licensing agreement with Xeris Biopharma (NASDAQ: XERS) for...

Company Drug

Eli Lilly Secures NMPA Approval for Emgality as Preventive Migraine Treatment in China

Fineline Cube Jan 11, 2024

Eli Lilly (NYSE: LLY) has received marketing approval from the National Medical Products Administration (NMPA)...

Company

C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials

Fineline Cube Jan 11, 2024

C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...

Company

Sanofi CEO Paul Hudson Rules Out GLP-1 Competition, Eyes Next-Gen Weight-Management Therapies

Fineline Cube Jan 11, 2024

Paul Hudson, CEO of Sanofi (NASDAQ: SNY), stated this week that the France-based pharmaceutical company...

Posts pagination

1 … 417 418 419 … 667

Recent updates

  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
  • Shanghai CureGene’s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial – First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance
  • Shenzhen Salubris Secures Chinese Approval for Xinfutai Plus – First Once-Weekly Teriparatide for High-Risk Postmenopausal Osteoporosis
  • Changchun GeneScience’s GenSci161 Receives FDA Clearance for Hidradenitis Suppurativa Clinical Trial – Novel Bispecific Antibody Targeting IL-1α/IL-1β
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Company Drug

Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy

Company Drug

Shanghai CureGene’s CG-0255 Receives NMPA Clearance for Ischemic Stroke Clinical Trial – First Thiol-Based P2Y12 Inhibitor Overcoming Clopidogrel Resistance

Company Drug

Shenzhen Salubris Secures Chinese Approval for Xinfutai Plus – First Once-Weekly Teriparatide for High-Risk Postmenopausal Osteoporosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.